Literature DB >> 25212704

Protein engineering for improved pharmacologic characteristics of established monoclonal antibody-based therapeutics.

Bernd Meibohm1.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25212704     DOI： 10.1007/s40262-014-0186-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  6 in total

Review 1.  Dual targeting strategies with bispecific antibodies.

Authors:  Roland E Kontermann
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 2.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

Review 3.  Arming antibodies: prospects and challenges for immunoconjugates.

Authors:  Anna M Wu; Peter D Senter
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 4.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

Review 5.  The challenge of indication extrapolation for infliximab biosimilars.

Authors:  Brian G Feagan; Denis Choquette; Subrata Ghosh; Dafna D Gladman; Vincent Ho; Bernd Meibohm; Guangyong Zou; Zhenhua Xu; Gopi Shankar; David C Sealey; Anthony S Russell
Journal:  Biologicals       Date:  2014-06-21       Impact factor: 1.856

6.  Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.

Authors:  Ahmed A Othman; Jonathan Q Tran; Meina T Tang; Sandeep Dutta
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447
  6 in total
  1 in total

1.  The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.

Authors:  Bishu Ganguly; Balaji Balasa; Lyubov Efros; Paul R Hinton; Stephen Hartman; Archana Thakur; Joanna M Xiong; Brian Schmidt; Randy R Robinson; Thierry Sornasse; Vladimir Vexler; James P Sheridan
Journal:  MAbs       Date:  2016-07-01       Impact factor: 5.857
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.